ClinicalTrials.gg
TerminatedNCT03335280Updated May 1, 2020

68Ga-citrate PET/MR Imaging for Glioma

An observational study in Glioma, sponsored by Susan Chang. Terminated at 1 site in United States. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2020-05-01.

Sponsored by Susan Chang · Observational

How we know

Why this study was terminated
Low Accrual

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
2
Ages
18 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 853 studies in Glioma with a site in United States — 144 open to participants now, 231 under way, 6 of them phase 3. Glioma · United States.

Enrollment
72nd of 77
2 · median 69
Started
2019
with 39 others
Observational
77 of 853
13 open now
Registered
528th of 853
by date

Among the 853 studies in Glioma with a site in United States, this one is the 72nd largest by enrollment of the 77 observational ones that give a count, is one of 40 that started in 2019, is one of 77 observational ones, and was the 528th registered.

Glioma

1,456 studies on the registry are indexed under Glioma; 351 are open to participants now.

Browse Glioma studies →

Open to participants now

144 of the 853 studies in Glioma with a site in United States are open now. Recruiting first, the newest first:

139 more — sign in →

All 144 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 267 Glioma studies recruiting now, 165 (62%) set no upper age limit and 57 (21%) stop at 75 or younger; 63 take children under 18; 15 take healthy volunteers.

This study: 18 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 853 studies in Glioma with a site in United States, or all of them as a file.
02

Study summary

This is a prospective, single center, open-label study in adult patients with presumed World Health Organization (WHO) grade 3 or 4 glioma who will be undergoing surgical resection as standard of care. In some cases, patients will have had biopsy. Study participants will undergo 68Ga-citrate Positron Emission Tomography / magnetic resonance (PET/MR) prior to surgery.

03

Conditions studied

  • Glioma

Browse trials for

04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Adults with WHO grade 3 or 4 glioma planning to undergo surgery with availability of immunohistochemistry of tissue

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • World Health Organization (WHO) grade 3 or 4 glioma planning to undergo surgery
  • Age >= 18 yrs.
  • performance status of >= 60
  • Ability to understand a written document, and the willingness to sign it.

Cohort A:

  • Positive for Phosphatase and Tensin Homolog (PTEN) deletion, confirmed by immunohistochemistry of tissue

Cohort B:

  • Negative for PTEN deletion, confirmed by immunohistochemistry of tissue biopsy

Exclusion criteria

Exclusion Criteria:

  • to Positron Emission Tomography (PET) imaging (e.g. pregnant or breast-feeding woman)
  • Contraindications to magnetic resonance (MR) imaging (e.g. pacemakers, metallic implants, etc.)
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
2 participants (actual)
Patient registry
No

Groups and cohorts

  • Positive for PTEN deletion

    Confirmed by immunohistochemistry of tissue biopsy

    Drug: 68Ga-citrate PET/MR

  • Negative for PTEN deletion

    Confirmed by immunohistochemistry of tissue biopsy

    Drug: 68Ga-citrate PET/MR

Interventions

  • Drug68Ga-citrate PET/MR

    Study participants will undergo the 68Ga-citrate PET/MR imaging after all screening and baseline assessments have been completed. Patient shall begin imaging between 120 and 360 minutes after the injection of the radiopharmaceutical. Coverage for the scan will extend from the patient's vertex to the neck. The entire imaging study will take roughly 90 minutes.

06

What researchers measure

Primary outcomes

  1. Maximum standardized uptake value (SUVmax)

    The location and extent of 68Ga-citrate uptake will be compared to both same day magnetic resonance imaging (MRI) and subsequent pathology. SUVmax will be the outcome of interest and summarized with descriptive measures. SUVmax will be compared via a two-sided two-sample equal-variance t-test between those patients positive for PTEN deletion and those negative for PTEN deletion.

    Time frame: 1 day

07

Study locations

1 site
  • University of California, San Francisco
    San Francisco, California 94143, United States
08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Feb 2019 to primary completion in Apr 2020, 13 months.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 18, 2017
First posted
Nov 7, 2017
StartActual
Feb 26, 2019
Primary completionActual
Apr 24, 2020
CompletionActual
Apr 24, 2020
Last update
May 1, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 1, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03335280
Lead sponsor
Susan Chang
Collaborators
American Brain Tumor Association
Responsible party
Susan Chang (Principal Investigator, University of California, San Francisco) — Sponsor-investigator
First posted
Nov 7, 2017
Start date
Feb 26, 2019
Primary completion
Apr 24, 2020
Completion
Apr 24, 2020
Last update
May 1, 2020

Study contacts

Susan Chang, MD
principal investigator · University of California, San Francisco

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Apr 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion